July 27, 1998
In a move designed to substantially expand its corporate-sponsored clinical drug research, Johns Hopkins Medicine has signed a non-exclusive agreement with Quintiles Transnational Corp., the world's largest contract pharmaceutical organization (CPO).
Under the agreement, Quintiles will collaborate with Johns Hopkins on clinical research opportunities. Quintiles Transnational Corp., headquartered near Research Triangle Park, N.C., specializes in accelerating the healthcare product development and launch process from preclinical trials through marketing and sales.
CenterWatch Inc., a Boston-based company that monitors the clinical trial industry, projects that for 1998, there will be about 9,000 clinical studies involving as many as 45,000 individual grants coming from the pharmaceutical industry.
"This new partnership could greatly expand our access to important clinical drug trials, giving our patients access to newer and possibly better medications," said Bart Chernow, M.D., vice dean for research and technology.
Working with medical institutions like Hopkins enhances Quintiles' ability to improve and accelerate drug development because it can offer the drug companies access to top clinical investigators, Chernow says.
In this fiscal year, Hopkins has 496 ongoing clinical trials.
"We anticipate that Quintiles would approach Hopkins regularly with clinical collaborative opportunities," Chernow says.
Anticipating an influx of new trials, Chernow has expanded a Hopkins Department of Medicine unit that coordinates clinical trials to include any School of Medicine departments appropriate to a Quintiles contract. The new Johns Hopkins Clinical Trials Unit will match a trial with all potential investigators, according to Unit director and endocrinologist Adrian Dobs, M.D. "This gives the drug industry an easier way to place its study and offers investigators a way to market their expertise in a coordinated and efficient way." In addition, the unit will provide other clinical trial research-related services to investigators. A master clinical trial agreement also in place with Quintiles will facilitate the start-up of studies.
Both Chernow and Dobs emphasize that every trial brought by Quintiles must pass Hopkins' rigorous ethical, institutional and scientific review process as well as have approval from the United States Food and Drug Administration.
Quintiles Transnational Corp., with 13,000 employees worldwide and offices in 28 countries, provides full-service contract research, sales and marketing, healthcare policy consulting and health information management services to the worldwide pharmaceutical, biotechnology, medical device and healthcare industries.
Quintiles Transnational Corp.
Pat Grebe (919)941-2000